I

Iambic Therapeutics

AI-driven discovery for oncology and neurology

IT Support Specialist

Full-TimePosted on 10/19/2026
$75k - $94.5k/yr
Junior, Mid
Bachelor's
San Diego, CA, USA
In PersonBased at the San Diego headquarters.
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • A bachelor's degree in information technology, computer science, or a related field, or equivalent work experience.
  • 2-5 years of experience in IT help desk support and/or system administration.
  • Experience with IT service management frameworks such as ITIL, and familiarity with incident, problem, change, and service level management best practices for third-party vendors.
  • Experience assisting with IT Operations projects related to deployment of new technology, process improvement, and information security.
  • Working knowledge of Windows, macOS, Linux, and mobile systems.
  • Experience with basic networking fundamentals, including TCP/IP, DNS, DHCP, VPNs, and wireless networks.
  • Proficiency in troubleshooting and resolving hardware and software issues on desktops, laptops, printers, and other end-user devices.
  • Familiarity with ticketing systems such as Jira and Zendesk, and remote desktop support tools.
  • Ability to explain technical issues clearly and concisely to non-technical users.
  • Ability to work independently, manage multiple tasks, and prioritize effectively in a fast-paced environment.
Responsibilities
  • Act as the first point of contact for clients and key stakeholders, build relationships to understand their needs, provide regular updates, and address issues.
  • Provide technical support and troubleshoot hardware, software, and network-related issues for end users in a timely manner, escalating issues to other IT team members or vendors when necessary.
  • Manage and prioritize incoming support tickets using the IT help desk system, ensuring reliable, high-quality IT service delivery that meets agreed-upon service level agreements and key performance indicators.
  • Support onboarding and offboarding for employees, interns, and consultants.
  • Create and maintain documentation, FAQs, and user guides to help end users resolve common issues independently.
  • Perform regular system updates, patches, and maintenance on end-user devices, including PCs, laptops, and printers.
  • Install, configure, and maintain lab software and hardware, including PCs, servers, network devices, and peripherals.
  • Analyze service delivery processes, identify improvement opportunities and potential risks, and suggest strategies to improve operational efficiency and quality, mitigate disruptions, and ensure business continuity.
  • Coordinate IT system changes with the IT team, ensuring changes are communicated, scheduled, and executed smoothly.
Desired Qualifications
  • Certifications such as CompTIA A+, Network+, Microsoft Certified: Modern Desktop Administrator, or similar.
  • Experience with endpoint/device management solutions such as Microsoft Intune or VMware Workspace ONE.
  • Experience managing technology labs, including hardware and software deployment and maintenance.

About the company

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Iambic filed an IPO on September 21, 2026, after $207.9 million cash.
  • Revenues reached $18 million over the twelve months ended June 30, 2026.
  • ClinicalTrials.gov shows IAM1363 recruiting 383 patients across 53 sites, including EU expansion.

What critics are saying

  • IAM1363 remains unproven; Phase 1 completion sits in 2028, delaying any approval.
  • Iambic's revenue still depends on partnerships; AbbVie and IPO proceeds fund the burn.
  • If AbbVie walks and IAM1363 fails, Iambic becomes a platform story without assets.

What makes Iambic Therapeutics unique

  • Enchant v3 spans 6,000+ molecular properties across 16 modalities, compressing discovery cycles.
  • AbbVie's September 21, 2026 collaboration validates Iambic's platform with another pharma heavyweight.
  • IAM1363 reached Phase 1 from AI design, proving platform-to-clinic execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Company Match
  • Unlimited Paid Time Off

Growth & Insights and Company News

6 month growth

0%

1 year growth

-2%

2 year growth

-3%
Antlers American
Oct 14th, 2026
Iambic prices $150M IPO at $16 per share, files IND for brain-penetrant cancer drug IAM217

Iambic Therapeutics, an AI-driven drug developer, priced its initial public offering at $16.00 per share, selling 9,375,000 shares for expected gross proceeds of $150.0 million. The underwriters have a 30-day option to buy up to 1,406,250 more shares. Shares are expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker "IAM." The offering is due to close on October 16, 2026. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are joint book-running managers. Iambic also submitted an Investigational New Drug application to the US Food and Drug Administration for IAM217, a potentially brain-penetrant KIF18A inhibitor. The Phase 1/2 trial would target triple-negative breast cancer, ovarian cancer, and other solid tumours. In a preclinical model, IAM217 produced about 90% regression of established intracranial tumours.

Intelligence360
Oct 5th, 2026
Iambic Therapeutics raises $66.5M to advance AI-driven drug discovery platform

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission to raise $66.5 million in new funding. The filing was made under Regulation D or Section 4(a)(5) of the Securities Act of 1933, which allows companies to sell securities without registration. Iambic Therapeutics is a drug discovery company that uses AI and automated chemistry and biology experimentation to accelerate pharmaceutical development. The company's platform integrates proprietary AI technologies, including Enchant and NeuralPLexer, for multimodal endpoint prediction. The company previously advanced a novel drug candidate to clinical trials in approximately two years and maintains a diverse preclinical pipeline. Iambic is led by Chief Executive Officer Tom Miller.

PR Newswire
Sep 21st, 2026
AbbVie partners with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology

AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.

Associated Press
Sep 21st, 2026
Iambic unveils Enchant v3 AI model with 41B parameters to accelerate drug discovery

Iambic, a clinical-stage life science and technology company, has launched Enchant v3, the latest version of its AI-driven multimodal transformer model for drug discovery and development. The model features 41 billion parameters and has been pretrained on 4.5 trillion tokens. Enchant v3 can predict more than 6,000 molecular properties across 16 biomedical modalities, including text, assay data, molecule structure, protein structure, images, multi-omics, biologics, clinical trial data, and pharmacokinetics. The system is designed to integrate diverse data sources and improve prediction accuracy as the model scales. Iambic initially launched Enchant in 2024. The company says its platform combines AI with automated chemistry and biology experimentation, and it previously discovered a novel drug candidate that advanced to clinical trials in approximately two years.

Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.